Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 11/20 | 0.38 |
| ▸ | PLG | P00747 | 7/20 | 0.38 |
| ▸ | PLAU | P00749 | 7/20 | 0.38 |
| ▸ | F2 | P00734 | 5/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.38 |
| ▸ | ST14 | Q9Y5Y6 | 3/20 | 0.34 |
| ▸ | HPN | P05981 | 2/20 | 0.34 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.34 |
| ▸ | F12 | P00748 | 2/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.33 |
| ▸ | PROC | P04070 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1624025 | 0.91 | F10 (0.39) | F10PLGPLAUF2PRSS1 | |
| SCHEMBL1624373 | 0.83 | PLAU (0.40) | F10PLGPLAUF2PRSS1 | |
| SCHEMBL1624532 | 0.74 | PLAU (0.40) | F10PLGPLAUF2PRSS1 | |
| SCHEMBL8111444 | 0.73 | PLAU (0.39) | F10PLGPLAUF2PRSS1 | |
| SCHEMBL1624027 | 0.70 | F10 (0.37) | F10PLGPLAUF2PRSS1 | |
| SCHEMBL1623950 | 0.62 | F2 (0.46) | F10PLGPLAUF2PRSS1 | |
| SCHEMBL1624971 | 0.60 | F2 (0.37) | F10PLGPLAUF2PRSS1 | |
| SCHEMBL1624029 | 0.60 | F10 (0.39) | F10PLGPLAUF2PRSS1 | |
| SCHEMBL1623823 | 0.60 | PLAU (0.45) | F10PLGPLAUF2PRSS1 | |
| Isophthalic Acid SCHEMBL5406230 | 0.59 | HPGD (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928137-B2 | Meta-benzamidine derivatives as serine protease inhibitors | TULARIK LIMITED (GB) | 2011-04-19 | — | — | US | disclosed |
| US-20070155790-A1 | Meta-benzamidine derivatives as serine protease inhibitors | LIEBESCHUETZ JOHN W | 2007-07-05 | — | — | US | disclosed |
| EP-1009758-B1 | META-BENZAMIDINE DERIVATIVES AS SERINE PROTEASE INHIBITORS | TULARIK LTD (GB) | 2005-06-01 | — | — | EP | disclosed |
| US-6740682-B2 | TREATMENT OF THROMBOTIC DISEASES, ASTHMA, EMPHYSEMA, CIRRHOSIS, ARTHRITIS, CARCINOMA, MELANOMA, RESTENOIS, ATHEROMA, TRAUMA, SHOCK AND REPERFUSION INJURY. | TULARIK LIMITED (GB) | 2004-05-25 | — | — | US | disclosed |
| US-20020055522-A1 | Meta-benzamidine derivatives as serine protease inhibitors | TULARIK LIMITED (GB) | 2002-05-09 | — | — | US | disclosed |
| EP-1009758-A1 | META-BENZAMIDINE DERIVATIVES AS SERINE PROTEASE INHIBITORS | Protherics Molecular Design Limited (GB) | 2000-06-21 | — | — | EP | disclosed |
| WO-1999011658-A1 | META-BENZAMIDINE DERIVATIVES AS SERIN PROTEASE INHIBITORS | PROTEUS MOLECULAR DESIGN LTD. (GB) | 1999-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055522-A1 | Meta-benzamidine derivatives as serine protease inhibitors | SERPINE1, PEPD, PRSS1 | F10 378/4885PLG 65/4885PLAU 87/4885 |
| US-20070155790-A1 | Meta-benzamidine derivatives as serine protease inhibitors | PEPD, SERPINE1, HPN | F10 292/4885PLG 46/4885PLAU 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.